Novartis reported that its Phase 3 pelacarsen program missed, adding to a run of cardiovascular outcomes trial failures across large-cap peers. The Swiss drugmaker said pelacarsen failed to show superiority versus control, widening the gap for antisense or lipid-related cardiovascular strategies currently under evaluation. For Amgen and Lilly in particular, the miss increases competitive pressure as capital and clinical attention shift toward the remaining cardiovascular outcomes assets. Pelacarsen’s setback also intensifies scrutiny on whether target engagement and biomarker shifts are sufficient proxies for clinical events. Now, the industry will focus on what the company does next—whether to pursue additional analyses, adjust development plans, or pivot to next-generation approaches within the same therapeutic area.